NCT02479581

Brief Summary

This study evaluates the enhanced recovery after surgery (ERAS) concept over conventional postoperative care in patients with heart valve disease undergoing cardiac surgery with cardiopulmonary bypass. Half of participants will adherence to the ERAS, while the other half will under the conventional postoperative care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
226

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 24, 2015

Completed
7 days until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

June 1, 2017

Status Verified

February 1, 2017

Enrollment Period

1.3 years

First QC Date

June 12, 2015

Last Update Submit

May 31, 2017

Conditions

Keywords

Enhanced Recovery after Surgery

Outcome Measures

Primary Outcomes (5)

  • The postoperative hospital time

    From pre-surgery to discharge, up to 4 weeks

  • Length of ICU stay

    From entering the ICU to roll out, up to 4 weeks

  • The time of readiness to discharge

    From pre-surgery to discharge, up to 4 weeks

  • The length of hospital stay

    From pre-surgery to discharge, up to 8 weeks

  • Hospitalization cost

    When the patient is discharged

Secondary Outcomes (13)

  • Perioperative major adverse events

    From pre-surgery to discharge, up to 4 weeks

  • Vasoactive drugs Support Hours

    From the start of drugs to stop them, up to 4 weeks

  • Postoperative tracheal tube time

    From the end of surgery to the removal of tracheal tube, up to 4 weeks

  • Duration of mechanical ventilation after surgery

    From the end of surgery to the recovery of spontaneous breathing, up to 4 weeks

  • Time to first bowel movement

    From the end of surgery to first exhaust, up to 2 weeks

  • +8 more secondary outcomes

Other Outcomes (1)

  • Questions to the participants' health

    Six month

Study Arms (2)

ERAS group

EXPERIMENTAL

Perioperative management follows the Enhanced Recovery after Surgery(ERAS) program

Procedure: ERAS group

Conventional control group

EXPERIMENTAL

Perioperative management follows the conventional program

Procedure: ERAS groupProcedure: Conventional control group

Interventions

ERAS groupPROCEDURE

Intravenous infusion of flucloxacillin sodium 1g an hour before operation

Also known as: "yifen®","Flucloxacillin"
ERAS group

Routine preoperative psychological preparation for patients.

Conventional control group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Heart function grade II - III (Using the cardiac function classification method formulated by American Heart Disease Institute)
  • The in - hospital was treated with extracorporeal circulation operation and general anesthesia.
  • Had a good cognition, and signed the informed consent.
  • Aged between 18 and 70.
  • The age, clinical examination and other generally situation of the two groups of patients had no statistical significance.

You may not qualify if:

  • Combined with other blood coagulation dysfunction, serious brain, liver and kidney dysfunction, endocrine system diseases and serious infectious disease.
  • Patients with severe mental disorders cannot cooperate with the treatment.
  • Emergency operation
  • Have taboo of Echocardiography and pulmonary catheterization by echocardiography.
  • Patients have been fitted with a pacemaker.
  • Allergic to erythropoietin.
  • Suspected or had alcohol, drug abuse history.
  • Spinal deformity or paravertebral lesions.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xiangya Hospital of Central South University

Changsha, Hunan, 410078, China

Location

Related Publications (4)

  • Bakker N, Cakir H, Doodeman HJ, Houdijk AP. Eight years of experience with Enhanced Recovery After Surgery in patients with colon cancer: Impact of measures to improve adherence. Surgery. 2015 Jun;157(6):1130-6. doi: 10.1016/j.surg.2015.01.016. Epub 2015 Mar 16.

  • Hoffmann H, Kettelhack C. Fast-track surgery--conditions and challenges in postsurgical treatment: a review of elements of translational research in enhanced recovery after surgery. Eur Surg Res. 2012;49(1):24-34. doi: 10.1159/000339859. Epub 2012 Jul 11.

  • Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet. 2003 Dec 6;362(9399):1921-8. doi: 10.1016/S0140-6736(03)14966-5.

  • Li M, Zhang J, Gan TJ, Qin G, Wang L, Zhu M, Zhang Z, Pan Y, Ye Z, Zhang F, Chen X, Lin G, Huang L, Luo W, Guo Q, Wang E. Enhanced recovery after surgery pathway for patients undergoing cardiac surgery: a randomized clinical trial. Eur J Cardiothorac Surg. 2018 Sep 1;54(3):491-497. doi: 10.1093/ejcts/ezy100.

MeSH Terms

Conditions

Heart Valve Diseases

Interventions

Methylprednisolone HemisuccinateScopolamineMorphineDexamethasone

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

MethylprednisolonePrednisolonePregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsScopolamine DerivativesTropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-RingMorphine DerivativesMorphinansOpiate AlkaloidsHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsSteroids, Fluorinated

Study Officials

  • e wang, phD

    Xiangya Hospital of Central South University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2015

First Posted

June 24, 2015

Study Start

July 1, 2015

Primary Completion

November 1, 2016

Study Completion

May 1, 2017

Last Updated

June 1, 2017

Record last verified: 2017-02

Locations